Biography
Dr. Lang is also the director of the UW Carbone Cancer Center’s circulating biomarker core and liquid biospecimen team, the co-leader of its tumor microenvironment program, and the clinical co-chair of its precision medicine molecular tumor board. He is a member of the American Society of Clinical Oncology (ASCO), the Society for Immunotherapy of Cancer, and the American Association of Cancer Research. Dr. Lang has received an ASCO Merit Award; a University of Wisconsin Helen Dickie Fellows Research Award; a Prostate Cancer Foundation Young Investigator Award; a Department of Medicine Puestow Junior Faculty Research Award; and a Division of Hematology, Medical Oncology and Palliative Care Award for Research Excellence.
CLINICAL SPECIALTIES: Dr. Lang is a medical oncologist who specializes in genitourinary (bladder, kidney, prostate and testicular) cancer.
RESEARCH INTERESTS: Dr. Lang has research interests in developmental therapeutics for prostate cancer. He is the lead principal investigator on the multi-PI Department of Defense Prostate Cancer Research Program, and the PI of a Prostate Cancer Foundation-funded project to investigate therapeutic targeting of AR-variant prostate cancer with a novel antibody drug conjugate. Dr. Lang also leads clinical trials that evaluate circulating tumor cells in solid tumor malignancies, efficacy of IMMU-132 in patients with metastatic castration-resistant prostate cancer and chemohormonal therapy in high-risk and oligo-metastatic prostate cancer.
Joshua Lang
University of Wisconsin Carbone Comprehensive Cancer Center, Madison
Topic: Metastatic Niche and Treatment Resistance